Comparing Aspire Biopharma (ASBP) and Its Peers

Aspire Biopharma (NASDAQ:ASBP) is one of 617 public companies in the “MED – BIOMED/GENE” industry, but how does it compare to its rivals? We will compare Aspire Biopharma to similar companies based on the strength of its risk, valuation, earnings, profitability, dividends, institutional ownership and analyst recommendations.

Profitability

This table compares Aspire Biopharma and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	N/A	N/A	-1,052.55%
Aspire Biopharma Competitors	-906.16%	-572.54%	-29.84%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Aspire Biopharma and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1	0	0	0	1.00
Aspire Biopharma Competitors	6250	12327	37926	1188	2.59

As a group, “MED – BIOMED/GENE” companies have a potential upside of 52.54%. Given Aspire Biopharma’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Aspire Biopharma has less favorable growth aspects than its rivals.

Valuation and Earnings

This table compares Aspire Biopharma and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Aspire Biopharma	N/A	-$12.54 million	-0.17
Aspire Biopharma Competitors	$888.58 million	-$44.34 million	10.18

Aspire Biopharma’s rivals have higher revenue, but lower earnings than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 25.8% of Aspire Biopharma shares are held by company insiders. Comparatively, 13.6% of shares of all “MED – BIOMED/GENE” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Aspire Biopharma has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Aspire Biopharma’s rivals have a beta of 0.90, suggesting that their average share price is 10% less volatile than the S&P 500.

Summary

Aspire Biopharma rivals beat Aspire Biopharma on 9 of the 13 factors compared.

About Aspire Biopharma

Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management. It develops formulation for a sublingually administered melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide, as well as formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and several other classes of drugs. The company was founded in 2021 and is based in Humacao, Puerto Rico.